EGFR and non-small cell lung carcinoma: , also showed that EGFR-mutant NSCLC patients with strong PD-L1 expressions had significantly shorter median PFS to EGFR-TKIs (7.07 months) than patients with weak (14.73 months, p < 0.001) or negative (12.70 months, p = 0.001) expressions21.